Collegium announces appeal courts upholds decision on Purdue ‘961 patent

Collegium Pharmaceutical announced that the U.S. Court of Appeals for the Federal Circuit has upheld the judgment of the Patent Trial and Appeal Board, PTAB, in its final decision that Purdue’s ‘961 patent, which Purdue has claimed is infringed by Xtampza ER, is invalid. The Federal Circuit’s decision affirming the invalidity of Purdue’s ‘961 patent confirms both that the PTAB had statutory authority to issue its final decision, and that the PTAB did correctly conclude that the 961 patent was invalid. “We applaud the Federal Circuit’s decision to confirm the authority of the PTAB and uphold its finding of invalidity of Purdue’s patent,” said Shirley Kuhlmann, Chief Administrative Officer and General Counsel of Collegium. “We will continue to vigorously defend Collegium’s intellectual property against claims of infringement.”